8-K: 10x Genomics Stockholders Re-Elect Directors, Ratify Auditor, and Approve Executive Compensation at Annual Meeting

10x Genomics, Inc. announced the successful re-election of two Class III directors, the ratification of Ernst & Young LLP as its independent auditor, and the advisory approval of executive compensation at its annual stockholders' meeting held on June 3, 2025.

Summary

• The annual meeting of stockholders for 10x Genomics, Inc. was held on June 3, 2025, via live webcast.
• A quorum was established with 108,937,350 shares present, representing approximately 87.7% of the 246,945,247 eligible votes.
• Stockholders approved the election of two Class III directors, Sri Kosaraju and Shehnaaz Suliman, each for a three-year term expiring at the Company's 2028 annual meeting.
• Sri Kosaraju received 189,313,724 votes For, 7,243,542 votes Against, 172,526 Abstentions, and 19,837,766 Broker Non-Votes.
• Shehnaaz Suliman received 168,973,468 votes For, 27,595,026 votes Against, 161,298 Abstentions, and 19,837,766 Broker Non-Votes.
• The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 215,766,816 votes For, 312,396 votes Against, and 488,346 Abstentions.
• Stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, with 164,321,765 votes For, 32,192,042 votes Against, 215,985 Abstentions, and 19,837,766 Broker Non-Votes.

Sentiment

Score: 7

Explanation: The successful passage of all proposals, including the re-election of directors and ratification of the auditor, indicates stable corporate governance and shareholder support for the company's current direction, despite some dissent on specific proposals.

Positives

• All three proposals submitted to the stockholders, including the election of directors, ratification of the independent auditor, and advisory approval of executive compensation, passed successfully.
• The high voter turnout, with approximately 87.7% of eligible votes represented, indicates strong shareholder engagement.
• The re-election of both Class III directors and the ratification of Ernst & Young LLP demonstrate continued shareholder confidence in the company's governance and financial oversight.

Negatives

• While approved, Shehnaaz Suliman received a notable 27,595,026 votes against her re-election, indicating some level of shareholder dissent.
• The non-binding advisory vote on executive compensation also saw significant opposition, with 32,192,042 votes against, suggesting a portion of shareholders are not fully satisfied with current executive pay practices.

Future Outlook

The document does not provide specific forward-looking statements or guidance regarding financial performance or strategic initiatives, focusing solely on the outcomes of the annual stockholder meeting.

Management Comments

• The report was signed by Eric S. Whitaker, Chief Legal Officer of 10x Genomics, Inc., on behalf of the registrant.

Industry Context

This filing details routine corporate governance matters for a publicly traded company in the biotechnology and genomics sector. The successful passage of all proposals is typical for annual meetings, reflecting standard operational procedures for maintaining corporate oversight and accountability.

Comparison to Industry Standards

• The re-election of directors and ratification of the auditor are standard governance practices across industries, including biotechnology. The level of 'against' votes for director Shehnaaz Suliman (approximately 14% of votes cast excluding broker non-votes) and executive compensation (approximately 16% of votes cast excluding broker non-votes) is within a range that, while not negligible, is generally not considered a major red flag compared to instances where such proposals fail or face significantly higher dissent (e.g., over 25-30% 'against' votes, which might prompt closer scrutiny by institutional investors or proxy advisors).

Corporate Governance

Stakeholder Impact

• Shareholders: Confirmed their support for the current board composition and auditor, and provided advisory feedback on executive compensation, indicating stability in corporate governance.
• Management: Received a mandate from shareholders for continued leadership and operations, with an advisory note on compensation.

Next Steps

• The re-elected Class III directors, Sri Kosaraju and Shehnaaz Suliman, will hold office until the Company's 2028 annual meeting of stockholders.
• Ernst & Young LLP will serve as the independent registered public accounting firm for the Company's fiscal year ending December 31, 2025.

Key Dates

Keywords

10x Genomics, TXG, SEC filing, 8-K, annual meeting, stockholder vote, corporate governance, director election, auditor ratification, executive compensation, biotechnology, genomics